PRECIGEN INC (PGEN) Stock Price, Quote, News and Overview
NASDAQ:PGEN - Nasdaq - US74017N1054 - Common Stock - Currency: USD
PGEN Quote, Performance and Key Statistics
1.85
-0.06 (-3.14%)
The current stock price of PGEN is 1.85 USD. In the past month the price increased by 1.65%. In the past year, price increased by 69.72%.
PGEN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.33 | 361.55B | ||
| AMGN | AMGEN INC | 13.31 | 156.09B | ||
| GILD | GILEAD SCIENCES INC | 15.38 | 148.05B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.04 | 100.23B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.4 | 61.11B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 57.73B | ||
| ARGX | ARGENX SE - ADR | 70.38 | 39.93B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.7 | 33.51B | ||
| BNTX | BIONTECH SE-ADR | N/A | 27.09B | ||
| INSM | INSMED INC | N/A | 24.24B | ||
| NTRA | NATERA INC | N/A | 21.63B | ||
| BIIB | BIOGEN INC | 8.43 | 19.77B |
Related stock screener links
About PGEN
Company Profile
Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. The company is headquartered in Germantown, Maryland and currently employs 143 full-time employees. The company went IPO on 2013-08-08. The Company’s proprietary technology platforms develop product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company has developed a pipeline of therapies across multiple indications. The Company’s segments include Biopharmaceuticals and Exemplar. The Biopharmaceuticals segment is primarily comprised of the Company's legal entities as well as royalty interests in therapeutics and therapeutic platforms from companies not controlled by the Company. The Exemplar is composed of Exemplar Genetics LLC, doing business as Precigen Exemplar, its wholly owned subsidiary focused on developing research models and services for healthcare research applications.
Company Info
PRECIGEN INC
20374 Seneca Meadows Parkway
Germantown MARYLAND 20876 US
CEO: Helen Sabzevari
Employees: 143
Phone: 13015569900
PRECIGEN INC / PGEN FAQ
What is the stock price of PRECIGEN INC today?
The current stock price of PGEN is 1.85 USD. The price decreased by -3.14% in the last trading session.
What is the ticker symbol for PRECIGEN INC stock?
The exchange symbol of PRECIGEN INC is PGEN and it is listed on the Nasdaq exchange.
On which exchange is PGEN stock listed?
PGEN stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for PRECIGEN INC stock?
10 analysts have analysed PGEN and the average price target is 6.12 USD. This implies a price increase of 230.81% is expected in the next year compared to the current price of 1.85. Check the PRECIGEN INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is PRECIGEN INC worth?
PRECIGEN INC (PGEN) has a market capitalization of 546.08M USD. This makes PGEN a Small Cap stock.
How many employees does PRECIGEN INC have?
PRECIGEN INC (PGEN) currently has 143 employees.
What are the support and resistance levels for PRECIGEN INC (PGEN) stock?
PRECIGEN INC (PGEN) has a support level at 1.81 and a resistance level at 1.92. Check the full technical report for a detailed analysis of PGEN support and resistance levels.
Is PRECIGEN INC (PGEN) expected to grow?
The Revenue of PRECIGEN INC (PGEN) is expected to grow by 232.31% in the next year. Check the estimates tab for more information on the PGEN EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy PRECIGEN INC (PGEN) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of PGEN, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of PGEN, evaluating the profitability, health, valuation and growth aspects
- PRECIGEN INC (PGEN) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- PRECIGEN INC (PGEN) Sales and EPS estimates to see what analysts future expectations are.
- PRECIGEN INC (PGEN) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- PRECIGEN INC (PGEN) Insider and Institutional Ownership to learn about the owners and their transactions.
- PRECIGEN INC (PGEN) Stock Chart to make your own analysis
- PRECIGEN INC (PGEN) Latest news and press-releases to stay up to date.
Does PRECIGEN INC (PGEN) stock pay dividends?
PGEN does not pay a dividend.
When does PRECIGEN INC (PGEN) report earnings?
PRECIGEN INC (PGEN) will report earnings on 2025-11-12, after the market close.
What is the Price/Earnings (PE) ratio of PRECIGEN INC (PGEN)?
PRECIGEN INC (PGEN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.32).
What is the Short Interest ratio of PRECIGEN INC (PGEN) stock?
The outstanding short interest for PRECIGEN INC (PGEN) is 10.77% of its float. Check the ownership tab for more information on the PGEN short interest.
PGEN Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to PGEN. When comparing the yearly performance of all stocks, PGEN is one of the better performing stocks in the market, outperforming 92.14% of all stocks.
PGEN Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to PGEN. PGEN has a great financial health rating, but its profitability evaluates not so good.
PGEN Financial Highlights
Over the last trailing twelve months PGEN reported a non-GAAP Earnings per Share(EPS) of -0.32. The EPS increased by 17.95% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -121.63% | ||
| ROE | -1013.39% | ||
| Debt/Equity | 0 |
PGEN Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 78% to PGEN. The Buy consensus is the average rating of analysts ratings from 10 analysts.
For the next year, analysts expect an EPS growth of -2.95% and a revenue growth 232.31% for PGEN